Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome

Targeted monoclonal antibody (mAb) therapies show great promise for the treatment of transplant rejection and autoimmune diseases by inducing more specific immunomodulatory effects than broadly immunosuppressive drugs routinely used. We recently described the therapeutic advantage of targeting CD45R...

Descripción completa

Detalles Bibliográficos
Autores principales: Besnard, Marine, Sérazin, Céline, Ossart, Jason, Moreau, Anne, Vimond, Nadège, Flippe, Léa, Sein, Hanna, Smith, Grace A., Pittaluga, Stefania, Ferré, Elise M.N., Usal, Claire, Anegon, Ignacio, Ranki, Annamari, Lionakis, Michail S., Peterson, Pärt, Guillonneau, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970675/
https://www.ncbi.nlm.nih.gov/pubmed/35167497
http://dx.doi.org/10.1172/JCI156507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970675/
https://www.ncbi.nlm.nih.gov/pubmed/35167497
http://dx.doi.org/10.1172/JCI156507

Ejemplares similares